PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-184.01%
Negative net income growth while AXSM stands at 0.00%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
-9.94%
Negative yoy D&A while AXSM is 0.00%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-368.86%
Negative yoy deferred tax while AXSM stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
368.86%
SBC growth of 368.86% while AXSM is zero at 0.00%. Bruce Berkowitz would see some additional share issuance that must be justified by expansions or retention needs.
55.40%
Working capital change of 55.40% while AXSM is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might affect near-term cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
252.95%
AP growth of 252.95% while AXSM is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might matter for short-term liquidity if expansions are large.
-12.95%
Negative yoy usage while AXSM is 0.00%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
200.11%
Growth of 200.11% while AXSM is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might reflect intangible expansions or partial write-offs.
-85.28%
Negative yoy CFO while AXSM is 0.00%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
80.16%
CapEx growth of 80.16% while AXSM is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
80.16%
We expand invests by 80.16% while AXSM is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
54.75%
Debt repayment growth of 54.75% while AXSM is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-0.41%
Negative yoy issuance while AXSM is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.